ClinicalTrials.gg

Biocad clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 94 studies whose lead sponsor is Biocad. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Biocad with Hoffmann-La Roche and Johnson & Johnson →

Pipeline: 10 programs

Each counted once: 10 with a study Biocad leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 5 of 6 with the most live studies.

Program
divozilimabPhase 3 · 3 live · Scleroderma, Systemic☆ Track
BCD-248Phase 3 · 2 live · Multiple Myeloma · primary completion Jul 2028☆ Track
pegdarbepoetin betaBCD131Phase 3 · 1 live · Anemia☆ Track
BCD-281Phase 3 · 1 live · Multiple Sclerosis, Relapsing-Remitting · primary completion Dec 2028☆ Track
AdalimumabAVT02Phase 3 · 0 live · Arthritis, Rheumatoid☆ Track

1 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Biocad’s own registered studies; Biocad’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Biocad’s studies test, most open studies first — 24 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 14 more

Coming up

4 of Biocad’s studies under way reach primary completion within a year, 2 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. 2J’27
  4. F
  5. M
  6. 1A
  7. 1M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add all 4 to your calendar (.ics) → With an account.

All 94 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1213%
  • Under way, not recruiting1516%
  • Completed5154%
  • Stopped early44%Terminated 2 · Withdrawn 2
  • Status unknown or other1213%

Phase

Where

  • Russian Federation69
  • Belarus20
  • Russia17
  • India7
  • Ukraine4
  • Thailand2

Over the years

  1. 11
  2. 12
  3. 13
  4. 14
  5. 15
  6. 1116
  7. 17
  8. 18
  9. 19
  10. 20
  11. 21
  12. 22
  13. 23
  14. 24
  15. 25
  16. 126

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Biocad.

  • Biocad
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    94 studies

Related but not counted here: SPH-BIOCAD (HK) Limited (affiliate).

Focus areas

Conditions Biocad leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 94. Browse all 94 →